Remegen Co., Ltd.

This early-phase study tested an experimental drug called RC108-ADC in 67 adults with advanced solid tumors that have a specific protein called c-Met. The main goals were to check the drug's safety and find the best dose. Researchers also looked at whether the drug could shrink t…

This study tested a new drug called telitacicept in 381 adults with active primary Sjogren's syndrome, a condition that causes dry eyes, dry mouth, and other symptoms. The goal was to see if the drug could reduce disease activity better than a placebo. Participants received injec…

This study tested a new drug called RC88 in 43 women whose ovarian, fallopian tube, or peritoneal cancer had stopped responding to platinum-based chemotherapy. The goal was to see if RC88 could shrink tumors and how safe it was. Participants had already tried at least three other…

This early-stage study tested a drug called telitacicept in 16 children with lupus. The goal was to measure how the drug moves through the body and to check for safety. This is not a cure, but a step toward better control of the disease.

This study tested an experimental drug called RC108 in 29 adults with advanced digestive system cancers that have a specific protein (c-Met). The goal was to see if the drug could shrink tumors or stop them from growing. Researchers also monitored side effects. The study is compl…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The trial is now complete, but results have not been released …

This study provided continued access to the experimental drug RC88 for patients with advanced solid tumors who had already participated in earlier research. The main goal was to further assess the safety and side effects of RC88 treatment. Researchers also measured how well the d…